---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004080"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:42:02.721826+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25

## Summary
- Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.
- Raised $10.75M in December private placement with SR One, Cormorant, Woodline.
- Cash and equivalents $51.2M at year-end; expected to fund operations into 1Q26.
- Q4 operating loss $9.5M; net loss $8.2M ($1.74/share).
- Full year 2024 net loss $38.5M ($10.15/share); no revenue.

## SEC filing metadata
- accession: 0001558370-25-004080
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/0001558370-25-004080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004080
- JSON: https://secwatch.observer/filing/0001558370-25-004080.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.